Gattefossé

Abstract Objective: This study aimed to develop an oral celastrol-loaded self-microemulsifying drug delivery system (Cel-SMEDDS) to enhance the therapeutic efficacy...

Abstract Entacapone is a catechol-O-methyltransferase (COMT) inhibitor, widely used for the symptomatic treatment of Parkinson’s disease. However, it presents setbacks...

by Gattefosse; original article first published at Drug Development and Delivery THE EVOLVING ROLE OF THE EXCIPIENT PARTNER The pharmaceutical...

Abstract Hygroscopicity poses a significant challenge in the formulation of pharmaceutical and nutraceutical products, as moisture absorption often leads to...

Abstract Tolcapone is a nitrocatechol-based drug used as adjuvant therapy in Parkinson’s Disease (PD). Despite being effective in managing PD-associated...

Abstract Background: Rebamipide (REB) is a poorly water-soluble drug with limited ocular bioavailability, necessitating advanced delivery strategies for sustained therapy in...

This poster has been presented at the 2026 World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical (PBP) Technology. Introduction Fused Deposition...

Abstract Oral delivery of peptides represents a promising alternative to invasive injectable therapies, offering improved patient adherence and convenience. Glucagon-like...

Abstract 3D printing drug formulations for personalized medicine is a growing research field and offers many opportunities to improve patient...

This poster has been presented at the 15th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, which took place in...